Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells
Age Group
0-9 years 10-17 years 18-26 years 27 years and older
0-9 years 10-17 years 18-26 years 27 years and older
Phase(s)
2 3
2 3
Genetic
Gene-modified (GM) T cell therapy
Trial Summary & Details
Ages: Child, Adult, Older Adult
Condition: Neoplasms
Condition: Neoplasms
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult subjects exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study.
Subjects who received at least one GM T cell infusion, will be asked to roll-over to this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.